Omics approaches in pancreatic adenocarcinoma
| dc.contributor.author | González Borja, Iranzu | |
| dc.contributor.author | Viúdez, Antonio | |
| dc.contributor.author | Goñi Irigoyen, Saioa | |
| dc.contributor.author | Santamaría Martínez, Enrique | |
| dc.contributor.author | Carrasco García, Estefanía | |
| dc.contributor.author | Pérez Sanz, Jairo | |
| dc.contributor.author | Hernández García, Irene | |
| dc.contributor.department | Ciencias de la Salud | es_ES |
| dc.contributor.department | Osasun Zientziak | eu |
| dc.contributor.funder | Gobierno de Navarra / Nafarroako Gobernua, Ref. 008-2018 | es |
| dc.date.accessioned | 2020-02-18T13:10:05Z | |
| dc.date.available | 2020-02-18T13:10:05Z | |
| dc.date.issued | 2019 | |
| dc.description.abstract | Pancreatic ductal adenocarcinoma, which represents 80% of pancreatic cancers, is mainly diagnosed when treatment with curative intent is not possible. Consequently, the overall five-year survival rate is extremely dismal—around 5% to 7%. In addition, pancreatic cancer is expected to become the second leading cause of cancer-related death by 2030. Therefore, advances in screening, prevention and treatment are urgently needed. Fortunately, a wide range of approaches could help shed light in this area. Beyond the use of cytological or histological samples focusing in diagnosis, a plethora of new approaches are currently being used for a deeper characterization of pancreatic ductal adenocarcinoma, including genetic, epigenetic, and/or proteo-transcriptomic techniques. Accordingly, the development of new analytical technologies using body fluids (blood, bile, urine, etc.) to analyze tumor derived molecules has become a priority in pancreatic ductal adenocarcinoma due to the hard accessibility to tumor samples. These types of technologies will lead us to improve the outcome of pancreatic ductal adenocarcinoma patients. | en |
| dc.description.sponsorship | This work was funded by grants from Department of Health from Government of Navarra (Ref. 008-2018), REFBIO II Pyrenees Biomedical Network from Programa INTERREG V-A España-Francia-Andora (Ref. BMK_PANC) and Sociedad Española de Oncología Médica (SEOM) to A.V. I.G.-B. is supported by a predoctoral fellowship from Department of Economic Development Government of Navarre 'Ayudas para la contratación de doctorandos y doctorandas por empresas y organismos de investigación y difusión de conocimientos: doctorados industriales 2018–2020'. | en |
| dc.format.extent | 19 p. | |
| dc.format.mimetype | application/pdf | en |
| dc.identifier.doi | 10.3390/cancers11081052 | |
| dc.identifier.issn | 2072-6694 | |
| dc.identifier.uri | https://academica-e.unavarra.es/handle/2454/36276 | |
| dc.language.iso | eng | en |
| dc.publisher | MDPI | en |
| dc.relation.ispartof | Cancers, 2019, 11 (8), 1052 | en |
| dc.relation.publisherversion | https://doi.org/10.3390/cancers11081052 | |
| dc.rights | © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. | en |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | Pancreatic adenocarcinoma | en |
| dc.subject | CtDNA | en |
| dc.subject | Proteomic | en |
| dc.subject | Genomic | en |
| dc.subject | Metabolomic | en |
| dc.subject | Lipidomic | en |
| dc.subject | FFPE | en |
| dc.subject | Tissue | en |
| dc.subject | Body fluids | en |
| dc.title | Omics approaches in pancreatic adenocarcinoma | en |
| dc.type | info:eu-repo/semantics/article | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 7945ddd5-cf8b-4927-bd7a-4ade2fb61f11 | |
| relation.isAuthorOfPublication | abacfd17-2b93-4d99-bae2-52053d57401e | |
| relation.isAuthorOfPublication.latestForDiscovery | 7945ddd5-cf8b-4927-bd7a-4ade2fb61f11 |